Hypophosphatemia induced by intravenous administration of saccharated ferric oxide. Another form of FGF23-related hypophosphatemia

Bone

Volumn 45, Issue 4, 2009, Pages 814-816

  Shimizu, Yuichiro ^a   Tada, Yuko ^b   Yamauchi, Mika ^b   Okamoto, Takaaki ^a   Suzuki, Hisanori ^a   Ito, Nobuaki ^a   Fukumoto, Seiji ^a   Sugimoto, Toshitsugu ^b   Fujita, Toshiro ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Fibroblast growth factor (FGF) 23; Hypophosphatemic rickets osteomalacia; Phosphate; Saccharated ferric oxide; Vitamin D

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; ALKALINE PHOSPHATASE; FIBROBLAST GROWTH FACTOR 23; IRON SACCHARATE; PHOSPHATE;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLOOD TRANSFUSION; BONE PAIN; CASE REPORT; CLINICAL FEATURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPOPHOSPHATEMIA; IRON DEFICIENCY ANEMIA; KNEE PAIN; MENORRHAGIA; MUSCLE WEAKNESS; PHOSPHATE BLOOD LEVEL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; VITAMIN BLOOD LEVEL;

ADULT; AGED, 80 AND OVER; FEMALE; FERRIC COMPOUNDS; FIBROBLAST GROWTH FACTORS; HUMANS; HYPOPHOSPHATEMIA; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED;

EID: 68849127439     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.06.017     Document Type: Article

References (22)

1. Shimada T., Mizutani S., Muto T., Yoneya T., Hino R., Takeda S., et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 6500-6505
2. Shimada T., Kakitani M., Yamazaki Y., Hasegawa H., Takeuchi Y., Fujita T., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 113 (2004) 561-568
3. Shimada T., Hasegawa H., Yamazaki Y., Muto T., Hino R., Takeuchi Y., et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 19 (2004) 429-435
4. Inoue Y., Segawa H., Kaneko I., Yamanaka S., Kusano K., Kawakami E., et al. Role of the vitamin D receptor in FGF23 action on phosphate metabolism. Biochem. J. 390 (2005) 325-331
5. Yamazaki Y., Okazaki R., Shibata M., Hasegawa Y., Satoh K., Tajima T., et al. Increased circulatory level of biologically active full length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J. Clin. Endocrinol. Metab. 87 (2002) 4957-4960
6. Jonsson K.B., Zahradnik R., Larsson T., White K.E., Sugimoto T., Imanishi Y., et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N. Engl. J. Med. 348 (2003) 1656-1663
7. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet. 26 (2000) 345-348
8. White K.E., Carn G., Lorenz-Depiereux B., Benet-Pages A., Strom T.M., and Econs M.J. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 86 (2001) 497-500
9. Lorenz-Depiereux B., Bastepe M., Benet-Pages A., Amyere M., Wagenstaller J., Muller-Barth U., et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat. Genet. 38 (2006) 1248-1250
10. Feng J.Q., Ward L.M., Liu S., Lu Y., Xie Y., Yuan B., et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat. Genet. 38 (2006) 1310-1315
11. Riminucci M., Collins M.T., Fedarko N.S., Cherman N., Corsi A., White K.E., et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J. Clin. Invest. 112 (2003) 683-692
12. Benet-Pages A., Orlik P., Strom T.M., and Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum. Mol. Genet. 14 (2005) 385-390
13. Topaz O., Shurman D.L., Bergman R., Indelman M., Ratajczak P., Mizrachi M., et al. Mutation in GALANT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat. Genet. 36 (2004) 579-581
14. Larrson T., Yu X., Davis S.I., Draman M.S., Mooney S.D., Cullen M.J., et al. A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J. Clin. Endocrinol. Metab. 90 (2005) 2424-2427
15. Araya K., Fukumoto S., Backenroth R., Takeuchi Y., Nakayama K., Ito N., et al. A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J. Clin. Endocrinol. Metab. 90 (2005) 5523-5527
16. Ichikawa S., Imel E.A., Kreiter M.L., Yu X., Mackenzie D.S., Sorenson A.H., et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J. Clin. Invest. 117 (2007) 2684-2691
17. Sato K., and Shiraki M. Saccharated ferric oxide-induced osteomalacia in Japan. Endocr. J. 45 (1998) 431-439
18. Walton R.J., and Bijvoet O.L. Nomogram for derivation of renal threshold phosphate concentration. Lancet 2 (1975) 309-310
19. Endo I., Fukumoto S., Ozono K., Namba N., Tanaka H., Inoue D., et al. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone 42 (2008) 1235-1239
20. Okada M., Imamura K., Fuchigami T., Omae T., Iida M., Nanishi F., et al. Osteomalacia caused by intravenous administration of saccharated ferric oxide for treatment of iron-deficiency anemia associated with nonspecific multiple ulcers of the small intestine: Report of two cases. (In Japanese) Jpn. J. Intern. Med. 71 (1982) 1566-1572
21. Schouten B.J., Doogue M.P., Soule S.G., and Hunt P.J. Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann. Clin. Biochem. 46 (2009) 167-169
22. Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG. FGF23 elevation and hypophosphataemia following intravenous iron polymaltose - a prospective study. J Clin Endocrinol Metab 2009;94(7):2332-7, doi:10.1210/jc.2008-2396.